Monthly vs. quarterly shots: can a simple switch boost ovarian suppression in young breast cancer?
NCT ID NCT07610733
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial will enroll 100 young women (ages 18-45) with hormone receptor-positive breast cancer who are already on a 3-month GnRH injection for ovarian suppression. Half will switch to a monthly injection, while the other half stays on the 3-month schedule. The study aims to see if the switch leads to better control of estrogen levels at 3 months, which is important for managing the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GnRH agonists (goserelin or leuprolide) plus endocrine therapy (aromatase inhibitor/tamoxifen ± CDK4/6 inhibitor)
What this could lead to
If successful, this could show that switching to a monthly GnRH injection provides better ovarian suppression, potentially improving treatment outcomes for young breast cancer patients.
What could go wrong
This is a small Phase 2 study (100 participants) and has not yet started recruiting. The primary endpoint is a hormone level, not a direct measure of cancer recurrence or survival, so benefits may not translate to better long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••